Increased mean platelet volume in patients with slow coronary flow

Şen, Nihat; Başar, Nurcan; Maden, Orhan; Özcan, Fırat; Özlü, Mehmet Fatih; Güngör, Ömer; Cagli, Kumral; Erbay, Ali Rıza; Balbay, Yücel

doi:10.1080/09537100802458969

Cited by 44 publications

(34 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On these grounds, MPV could be accepted as a parameter of platelet activity and has become a prognostic factor in coronary heart disease [25]. Previous studies have demonstrated a close relationship between MPV and AMI [8], unstable coronary syndromes [26], slow coronary ow [27] and coronary artery ectasia development [28]. High MPV values were found to be associated with unsuccessful reperfusion a er both primary percutaneous coronary intervention and brinolytic therapy [29,30].…”

Section: Discussionmentioning

confidence: 99%

Relationship between mean platelet volume and left ventricular systolic function in patients with metabolic syndrome and ST-elevation myocardial infarction

Yazici

Poyraz²,

Şen³

et al. 2011

CIM

Self Cite

View full text Add to dashboard Cite

Relationship between mean platelet volume and le ventricular systolic function in patients with metabolic syndrome and ST-elevation myocardial infarction Abstract Purpose: Mean platelet volume (MPV) is an indicator of platelet activation, which is a central process in the pathophysiology of coronary heart disease. Metabolic syndrome (MS) may lead to worsened le ventricular systolic function by causing recurrent thrombotic events and by aggravating systemic in ammation in the course of acute myocardial infarction. e present study was designed to investigate the relationship between MPV and le ventricular systolic function in patients with metabolic syndrome who had rst ST-elevation myocardial infarction.Methods: MPV was measured on admission in 33 patients who had preserved le ventricle systolic function (mean age, 56.9±10.2 years) and in 48 patients who had depressed le ventricle systolic function (mean age, 57.9±10.5 years) with metabolic syndrome and rst ST elevation myocardial infarction. Depressed le ventricle systolic function was de ned as ≤50% ejection fraction value. MPV levels were compared in the two groups.Results: MPV was signi cantly higher in patients with depressed le ventricle systolic function in comparison with patients showing preserved le ventricle systolic function (p=0.02). Logistic regression analysis showed an independent relationship between MPV and deteriorated le ventricular systolic function, even a er adjustment for potential confounders (1.08 (1.04-1.20), CI: 95%, p=0.02).Conclusions: Increased MPV on admission can be associated with degree of le ventricle systolic depression in patients with metabolic syndrome with rst ST-elevation myocardial infarction. MPV may prove to be useful as a prognostic marker in patients with metabolic syndrome and ST elevation MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between mean platelet volume and left ventricular systolic function in patients with metabolic syndrome and ST-elevation myocardial infarction

Yazici

Poyraz²,

Şen³

et al. 2011

CIM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, it is detected that PTX-3 is also produced at atherosclerotic plaque. Demonstration of correlated increase of PTX-3 secreted from neutrophils and platelet aggregation in acute coronary syndrome (20) may be one reason of increased platelet aggregation shown in patients with SCF (21). Level of PTX-3 was shown to increase in acute atherothrombosis in CAD, and was accepted as a predictor of mortality (20).…”

Section: Discussionmentioning

confidence: 99%

Increased pentraxin-3 level in patients with slow coronary flow

Büyükkaya¹,

Karakaş²,

Kurt³

et al. 2013

Turk J Bioch

Self Cite

View full text Add to dashboard Cite

Amaç: Koroner yavaş akım (YKA), anjiyografisinde normal koroner arterlere sahip olup opak maddenin koronerlerin distaline geç ulaşması ile karakterizedir. YKA'ın inflamasyon ve yüksek duyarlıklı C reaktif protein (hs-CRP) gibi inflamatuvar belirteçler ile ilişkisi bilinmektedir. Pentraksin-3 (PTX-3), yeni bir akut faz reaktanı olup CRP gibi pentraksin ailesinin bir üyesidir. Biz bu çalışmada YKA hastalarında PTX-3 düzeyini araştırdık. Yöntem: Çalışmaya YKA saptanan 25 hasta ve koroner arter hastalığı (KAH) olan 26 hasta alındı. Yavaş koroner akım ve KAH tanısı koroner anjiyografi ile konuldu. Kardiyoloji polikliniğine başvurmuş iskemik bulguların gözlenmediği 24 sağlıklı birey kontrol grubu olarak alındı. Tüm grubun PTX-3 ve hs-CRP çalışıldı. Bulgular: KYA grubundaki hastaların PTX-3 ve hs-CRP seviyesi kontrol grubuna göre daha yüksekti(sırasıyla 0.52 ± 0.2 ng/ml ve 0.20 ±0.08 ng/ml, p< 0.001; 1.1±0.4 mg/dl ve 0.6±0.5 mg/dl, p< 0.001). Ancak KYA grubu ile KAH grubu arasında serum PTX-3 ile hs-CRP seviyesinde fark bulunmadı (sırasıyla 0.52 ± 0.2 ng/ml ve 0.58 ± 0.18 ng/ml, p: 0.24; 1.1 ± 0.4 mg/dl ve 1.1 ± 0.6 mg/dl; p: 0.32). Korelasyon analizi sonucu serum PTX-3 ve hs-CRP seviyeleri birbirleriyle ilişkili bulundu. (Rho=0.34, p: 0.003). Sonuç: PTX-3, yeni bir inflamatuvar marker olup YKA olan hastalarda yükselmiştir ve bu hastalarda inflamatuvar durumu yansıtmada bir belirteçtir.Objective: Slow coronary flow (SCF) is defined as late opacification in the epicardial coronary artery without significant stenosis on the coronary angiographic images. The association between SCF and inflammation and inflammatory markers such as high sensitivity-C reactive protein (hs-CRP) is well known. Pentraxin-3 (PTX-3), a new acute phase reactant, is a member of pentraxine family like hs-CRP. We investigated the association between PTX-3 and hs-CRP in patients with SCF. Method: The study included 25 patients with SCF and 26 patients with coronary artery disease (CAD) whose diagnoses were made by coronary angiography. The control group consisted of 24 healthy subjects admitted cardiology outpatient clinic without any sign of ischemia. From the all study population PTX-3 and hs-CRP levels were measured. Results: The SCF group had significantly increased PTX-3 and hs-CRP levels than the control group (0.52 ± 0.2 ng/ml vs 0.20 ±0.08 ng/ml, p< 0.001; 1.1±0.4 mg/dl vs 0.6±0.5 mg/dl, p< 0.001, respectively). However there were no differences in levels of PTX-3 and hs-CRP between the SCF and the CAD groups (0.52 ± 0.2 ng/ml vs 0.58 ± 0.18 ng/ml, p: 0.24; 1.1 ± 0.4 mg/dl vs 1.1 ± 0.6 mg/dl; p: 0.32, respectively). Correlation analysis revealed a positive correlation between serum PTX-3 levels and hs-CRP levels (r=0.34, p: 0.003). Conclusion: PTX-3, a novel inflammatory marker, is elevated in patients with SCF and may be reflecting the inflammatory status in patients with SCF.Anahtar Kelimeler: Koroner yavaş akım, hs-CRP, inflamasyon, Pentraksin-3.

show abstract

“…However, patients' cardiac, hepatic and respiratory system characteristics were also not investigated in the study. Pathologies relating to these systems had the ability to cause changes in MPV values [19][20][21][22] . Also in that study, it was not clear how the diagnosis of synovitis was made.…”

Section: Discussionmentioning

confidence: 99%